Patrick N. Harter

Paul Ehrlich Str. 40
Frankfurt Am Main, HE 60590, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 226 publications

Patterns of radiological response to procarbazine and CCNU polychemotherapy in patients with oligodendroglioma.

Patterns of radiological response to procarbazine and CCNU polychemotherapy in patients with oligodendroglioma.

Journal: Neuro-oncology advances
Published: March 19, 2026

Identification of prognostically relevant residual tumor in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET.

Identification of prognostically relevant residual tumor in glioblastoma after surgery: A comparative analysis of MR-based RANO resect classes vs. [18F]FET PET.

Journal: Neuro-oncology
Published: March 18, 2026

Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging Features.

Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging Features.

Journal: Neurology
Published: March 17, 2026

Interlaboratory performance testing on EPIC v2.0 CNS tumor profiling demonstrates high reproducibility of tumor classification but reveals the need for harmonized copy number variation reporting.

Interlaboratory performance testing on EPIC v2.0 CNS tumor profiling demonstrates high reproducibility of tumor classification but reveals the need for harmonized copy number variation reporting.

Journal: Brain pathology (Zurich, Switzerland)
Published: March 13, 2026

PET RANO 1.0 vs. RANO 2.0 criteria for trial eligibility in IDH-wildtype glioblastoma: a retrospective, comparative study.

PET RANO 1.0 vs. RANO 2.0 criteria for trial eligibility in IDH-wildtype glioblastoma: a retrospective, comparative study.

Journal: Neuro-oncology
Published: March 11, 2026

Loss of meningothelial identity and mesenchymal fate switching in NF2-mutant meningiomas.

Loss of meningothelial identity and mesenchymal fate switching in NF2-mutant meningiomas.

Journal: Acta neuropathologica
Published: February 21, 2026

Quality-of-life and detailed functional outcome after IONM-aided microsurgical resection of cervical and thoracic intramedullary spinal cord tumors in adults.

Quality-of-life and detailed functional outcome after IONM-aided microsurgical resection of cervical and thoracic intramedullary spinal cord tumors in adults.

Journal: Acta neurochirurgica
Published: January 13, 2026

The prognostic significance of TSPO-PET imaging in IDH-mutant glioma: a single-center, retrospective study.

The prognostic significance of TSPO-PET imaging in IDH-mutant glioma: a single-center, retrospective study.

Journal: European journal of nuclear medicine and molecular imaging
Published: January 06, 2026

Methylation profiling and alternative classification approaches in a glioma-enriched FFPE stereotaxic biopsy cohort.

Methylation profiling and alternative classification approaches in a glioma-enriched FFPE stereotaxic biopsy cohort.

Journal: Acta neuropathologica communications
Published: December 23, 2025

Peritumoral brain zone oxygen extraction fraction is associated with tumor Ki-67 index in untreated glioblastoma.

Peritumoral brain zone oxygen extraction fraction is associated with tumor Ki-67 index in untreated glioblastoma.

Journal: Neuro-oncology advances
Published: December 19, 2025

Primary mismatch repair deficient glioma, IDH-wildtype and H3-wildtype: A giant cell tumor with potential for long-term survival occurring at all ages.

Primary mismatch repair deficient glioma, IDH-wildtype and H3-wildtype: A giant cell tumor with potential for long-term survival occurring at all ages.

Journal: Neuro-oncology
Published: December 15, 2025

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

Primary Mismatch Repair Deficient Glioma (PMMRDG), IDH-wildtype and H3-wildtype: A Giant Cell Tumor with Potential for Long-Term Survival Occurring at all Ages.

Journal: Neuro-oncology
Published: December 15, 2025
Showing 1-12 of 226

Last Updated: 09/26/2026